Efficacy of adalimumab in sarcoidosis patients who developed intolerance to infliximab

Crommelin, Heleen A.; Burg, Leone M. van der; Vorselaars, Adriane D.M.; Drent, Marjolein; Moorsel, Coline H.M. van; Rijkers, Ger T.; Deneer, Vera H.M.; Grutters, Jan C.

doi:10.1016/j.rmed.2016.04.011

Cited by 72 publications

(28 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…adalimumab has been found to be effective in some patients [57][58][59]. Other anti-TNF agents such as golimumab and etanercept were not found to be effective in most sarcoidosis patients [60][61][62].…”

Section: Discussionmentioning

confidence: 99%

Delphi consensus recommendations for a treatment algorithm in pulmonary sarcoidosis

et al. 2020

Self Cite

View full text Add to dashboard Cite

Pulmonary sarcoidosis presents substantial management challenges, with limited evidence on effective therapies and phenotypes. In the absence of definitive evidence, expert consensus can supply clinically useful guidance in medicine. An international panel of 26 experts participated in a Delphi process to identify consensus on pharmacological management in sarcoidosis with the development of preliminary recommendations.The modified Delphi process used three rounds. The first round focused on qualitative data collection with open-ended questions to ensure comprehensive inclusion of expert concepts. Rounds 2 and 3 applied quantitative assessments using an 11-point Likert scale to identify consensus.Key consensus points included glucocorticoids as initial therapy for most patients, with non-biologics (immunomodulators), usually methotrexate, considered in severe or extrapulmonary disease requiring prolonged treatment, or as a steroid-sparing intervention in cases with high risk of steroid toxicity. Biologic therapies might be considered as additive therapy if non-biologics are insufficiently effective or are not tolerated with initial biologic therapy, usually with a tumour necrosis factor-α inhibitor, typically infliximab.The Delphi methodology provided a platform to gain potentially valuable insight and interim guidance while awaiting evidenced-based contributions.

show abstract

Section: Discussionmentioning

confidence: 99%

Delphi consensus recommendations for a treatment algorithm in pulmonary sarcoidosis

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…Moreover, the TNF inhibitor may be changed to another one in case of lack of response. 140 As previously reported, caution must be observed with such biological agents, as paradoxical systemic sarcoidosis and sarcoid uveitis have been reported. 141,142 Other Biologics New therapeutic approaches have been studied in refractory sarcoidosis, with immunosuppressants like rituximab (RTX), tocilizumab (TCZ), or other biologics used in inflammatory diseases, especially Janus kinase (JAK) inhibitors.…”

Section: Anti-tnf-α Treatmentmentioning

confidence: 83%

Ocular Sarcoidosis

Sève

Jamilloux

Tilikete

et al. 2020

Semin Respir Crit Care Med

View full text Add to dashboard Cite

Sarcoidosis is one of the leading causes of inflammatory eye disease. Any part of the eye and its adnexal tissues can be involved. Uveitis and optic neuropathy are the main manifestations, which may require systemic treatment. Two groups of patients with sarcoid uveitis can be distinguished: one of either sex and any ethnicity in which ophthalmological findings are various and another group of elderly Caucasian women with mostly chronic posterior uveitis. Clinically isolated uveitis revealing sarcoidosis remains a strictly ocular condition in a large majority of cases. Although it can be a serious condition involving functional prognosis, early recognition in addition to a growing therapeutic arsenal (including intravitreal implant) has improved the visual prognosis of the disease in recent years. Systemic corticosteroids are indicated when uveitis does not respond to topical corticosteroids or when there is bilateral posterior involvement, especially macular edema. In up to 30% of the cases that require an unacceptable dosage of corticosteroids to maintain remission, additional immunosuppression is used, especially methotrexate. As with other forms of severe noninfectious uveitis, monoclonal antibodies against tumor necrosis factor-α have been used. However, only very rarely does sarcoid uveitis fail to respond to combined corticosteroids and methotrexate therapy, a situation that should suggest either poor adherence or another granulomatous disease. Optic neuropathy often affects women of African and Caribbean origins. Some authors recommend that patients should be treated with high-dose of corticosteroids and concurrent immunosuppression from the onset of this manifestation, which is associated with a poorer outcome.

show abstract

“…104 The use of lowdose MTX might increase TNFi efficacy with re-increased IFX or ADA serum levels linked to antidrug antibody elimination. Moreover, one TNFi can be changed to another in cases of lack of response and immunization, if TNFi blood levels are in the normal range 105 In non-immunized patients with low drug concentrations, reducing the intervals between two injections should be considered. 102…”

Section: Tnf-α Inhibitorsmentioning

confidence: 99%

<p>Refractory Sarcoidosis: A Review</p>

Jammal

Jamilloux

Gerfaud‐Valentin

et al. 2020

TCRM

View full text Add to dashboard Cite

Sarcoidosis is a multi-system disease of unknown etiology characterized by granuloma formation in various organs (especially lung and mediastinohilar lymph nodes). In more than half of patients, the disease resolves spontaneously. When indicated, it usually responds to corticosteroids, the first-line treatment, but some patients may not respond or tolerate them. An absence of treatment response is rare and urges for verifying the absence of a diagnosis error, the good adherence of the treatment, the presence of active lesions susceptible to respond since fibrotic lesions are irreversible. That is when second-line treatments, immunosuppressants (methotrexate, leflunomide, azathioprine, mycophenolate mofetil, hydroxychloroquine), should be considered. Methotrexate is the only first-line immunosuppressant validated by a randomized controlled trial. Refractory sarcoidosis is not yet a well-defined condition, but it remains a real challenge for the physicians. Herein, we considered refractory sarcoidosis as a disease in which second-line treatments are not sufficient to achieve satisfying disease control or satisfying corticosteroids tapering. Tumor necrosis alpha inhibitors, third-line treatments, have been validated through randomized controlled trials. There are currently no guidelines or recommendations regarding refractory sarcoidosis. Moreover, criteria defining non-response to treatment need to be clearly specified. The delay to achieve response to organ involvement and drugs also should be defined. In the past ten years, the efficacy of several immunosuppressants beforehand used in other autoimmune or inflammatory diseases was reported in refractory cases series. Among them, anti-CD20 antibodies (rituximab), repository corticotrophin injection, and anti-JAK therapy anti-interleukin-6 receptor monoclonal antibody (tocilizumab) were the main reported. Unfortunately, no clinical trial is available to validate their use in the case of sarcoidosis. Currently, other immunosuppressants such as JAK inhibitors are on trial to assess their efficacy in sarcoidosis. In this review, we propose to summarize the state of the art regarding the use of immunosuppressants and their management in the case of refractory or multidrugresistant sarcoidosis.

show abstract

Efficacy of adalimumab in sarcoidosis patients who developed intolerance to infliximab

Cited by 72 publications

References 38 publications

Delphi consensus recommendations for a treatment algorithm in pulmonary sarcoidosis

Delphi consensus recommendations for a treatment algorithm in pulmonary sarcoidosis

Ocular Sarcoidosis

<p>Refractory Sarcoidosis: A Review</p>

Contact Info

Product

Resources

About